Acorah Software Products - Accounts Production 18.1.170 false true 31 January 2025 1 February 2024 false 1 February 2025 31 January 2026 31 January 2026 07914323 Dr Adel Hafez Abdelmeged Mrs Sarah Seifelnasr Mrs Sarah Seifelnasr iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 07914323 2025-01-31 07914323 2026-01-31 07914323 2025-02-01 2026-01-31 07914323 frs-core:CurrentFinancialInstruments 2026-01-31 07914323 frs-core:ComputerEquipment 2026-01-31 07914323 frs-core:ComputerEquipment 2025-02-01 2026-01-31 07914323 frs-core:ComputerEquipment 2025-01-31 07914323 frs-core:RevaluationReserve 2025-01-31 07914323 frs-core:RevaluationReserve 2026-01-31 07914323 frs-core:ShareCapital 2026-01-31 07914323 frs-core:RetainedEarningsAccumulatedLosses 2025-02-01 2026-01-31 07914323 frs-core:RetainedEarningsAccumulatedLosses frs-core:PreviouslyStatedAmount 2025-01-31 07914323 frs-core:RetainedEarningsAccumulatedLosses 2026-01-31 07914323 frs-bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 07914323 frs-bus:FilletedAccounts 2025-02-01 2026-01-31 07914323 frs-bus:SmallEntities 2025-02-01 2026-01-31 07914323 frs-bus:AuditExempt-NoAccountantsReport 2025-02-01 2026-01-31 07914323 frs-bus:SmallCompaniesRegimeForAccounts 2025-02-01 2026-01-31 07914323 frs-core:CostValuation 2025-01-31 07914323 frs-core:CostValuation 2026-01-31 07914323 frs-core:ProvisionsForImpairmentInvestments 2025-01-31 07914323 frs-core:ProvisionsForImpairmentInvestments 2026-01-31 07914323 frs-bus:Director1 2025-02-01 2026-01-31 07914323 frs-bus:Director2 2025-02-01 2026-01-31 07914323 frs-bus:CompanySecretary1 2025-02-01 2026-01-31 07914323 frs-countries:EnglandWales 2025-02-01 2026-01-31 07914323 2024-01-31 07914323 2025-01-31 07914323 2024-02-01 2025-01-31 07914323 frs-core:CurrentFinancialInstruments 2025-01-31 07914323 frs-core:RevaluationReserve 2025-01-31 07914323 frs-core:ShareCapital 2025-01-31 07914323 frs-core:RetainedEarningsAccumulatedLosses 2025-01-31
Registered number: 07914323
Adsa Medical Consulting Ltd
Unaudited Financial Statements
For The Year Ended 31 January 2026
The Arkk Alliance Ltd
Adsa Medical Consulting Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—4

Page 1
Adsa Medical Consulting Ltd
Balance Sheet
As At 31 January 2026
Balance Sheet
Registered number: 07914323

| 2026 | 2025
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Investments | 5 |  | 40,000 |  | 40,000
|  |  | 40,000 |  | 40,000
CURRENT ASSETS
Cash at bank and in hand |  | 256 |  | 3,541 |
|  | 256 |  | 3,541 |
Creditors: Amounts Falling Due Within One Year | 6 | (25,281 ) |  | (18,552 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | (25,025 ) |  | (15,011 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 14,975 |  | 24,989
NET ASSETS |  |  | 14,975 |  | 24,989
CAPITAL AND RESERVES
Called up share capital | 7 |  | 100 |  | 100
Revaluation reserve | 8 |  | 643 |  | 643
Profit and Loss Account |  |  | 14,232 |  | 24,246
SHAREHOLDERS' FUNDS |  |  | 14,975 |  | 24,989

Page 1
Page 2
Adsa Medical Consulting Ltd
Balance Sheet (continued)
As At 31 January 2026
For the year ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Dr Adel Hafez Abdelmeged Director
15th April 2026

The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Adsa Medical Consulting Ltd
Notes to the Financial Statements
For The Year Ended 31 January 2026
Notes to the Financial Statements
1. General Information
Adsa Medical Consulting Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 07914323 . The registered office is 1st Floor, 20-22 Station Road, Knowle, Solihull, West Midlands, B93 0HT.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment | 10% Straight Line

3. Average Number of Employees
Average number of employees, including directors, during the year was:

| 2026 |  | 2025
--- | --- | --- | ---
Office and administration | 2 |  | 2
| 2 |  | 2

4. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 1 February 2025 | 1,498
As at 31 January 2026 | 1,498
Depreciation
As at 1 February 2025 | 1,498
As at 31 January 2026 | 1,498
Net Book Value
As at 31 January 2026 | -
As at 1 February 2025 | -

Page 3
Page 4
Adsa Medical Consulting Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 January 2026
5. Investments

| Other
--- | ---
| £
Cost or Valuation
As at 1 February 2025 | 40,000
As at 31 January 2026 | 40,000
Provision
As at 1 February 2025 | -
As at 31 January 2026 | -
Net Book Value
As at 31 January 2026 | 40,000
As at 1 February 2025 | 40,000

6. Creditors: Amounts Falling Due Within One Year

| 2026 |  | 2025
--- | --- | --- | ---
| £ |  | £
Other taxes and social security | 62 |  | -
Directors' loan accounts | 25,219 |  | 18,552
| 25,281 |  | 18,552

7. Share Capital

| 2026 |  | 2025
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 100 |  | 100

8. Reserves

| Revaluation reserve | Profit and Loss Account
--- | --- | ---
| £ | £
As at 1 February 2025 | 643 | 24,246
Loss for the year and total comprehensive income | - | (9,014 )
Dividends paid | - | (1,000)
As at 31 January 2026 | 643 | 14,232

Page 4